Fellowship · Chicago, IL
Sponsored by University of Chicago Medical Center
A multisociety Delphi consensus statement on new fatty liver disease nomenclature.
Journal of hepatology · 2023 · 2,696 citations · Mary Rinella
A multisociety Delphi consensus statement on new fatty liver disease nomenclature.
Hepatology (Baltimore, Md.) · 2023 · 2,397 citations · Mary Rinella
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.
The New England journal of medicine · 2024 · 1,637 citations · Mary Rinella
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease.
Hepatology (Baltimore, Md.) · 2023 · 2,087 citations · Mary Rinella
Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.
The New England journal of medicine · 2025 · 750 citations · Mary Rinella
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD.
Gastroenterology · 2021 · 2,418 citations · David Rubin
Non-alcoholic fatty liver disease.
Lancet (London, England) · 2021 · 2,293 citations · Mary Rinella
Global evolution of inflammatory bowel disease across epidemiologic stages.
Nature · 2025 · 326 citations · David Rubin